ReviewGastroenterologia y hepatologia2020
COVID-19 and liver disease: An update.
Review in Gastroenterologia y hepatologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Assessing the Long-Term Impact of the COVID-19 Pandemic on Hospital Outcomes in Patients with Decompensated Liver Cirrhosis.Medicina (Kaunas, Lithuania) · 2026Article
- Hepatitis B virus associated with severe acute respiratory syndrome coronavirus 2 infection: a case report.Journal of medical case reports · 2025Article
- IGSF1: a biomarker for predicting prognosis, immunotherapy response, and drug candidates in COVID-19 combined hepatocellular carcinoma.Discover oncology · 2024Article
- [Gastrointestinal manifestations and liver disorders in patients with COVID-19].Revista medica del Instituto Mexicano del Seguro Social · 2024Observational
- Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease.International journal of molecular sciences · 2024Observational
- The Impact of COVID-19 Pandemic Lockdown on the Relationship between Pediatric MAFLD and Renal Function.Journal of clinical medicine · 2023Article
- COVID-19-induced transaminitis and hyperbilirubinemia: Presentation and outcomes.World journal of gastroenterology · 2023Article
- Liver involvement in patients with COVID-19 infection: A comprehensive overview of diagnostic imaging features.World journal of gastroenterology · 2023Review
- Impact of COVID-19 pandemic and anti-pandemic measures on tuberculosis, viral hepatitis, HIV/AIDS and malaria-A systematic review.PLOS global public health · 2023Article
- Article
- Hepatitis B, C and human immunodeficiency virus knowledge among the general greek population: results from the Hprolipsis nationwide survey.BMC public health · 2022Article
- Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma.Journal of clinical medicine · 2022Review
- Impact of SARS-CoV-2 infection on liver disease.Advances in laboratory medicine · 2022Review
- Article
- COVID-19 and Liver Surgery: How the Pandemic Affected an Italian Medium-Volume HBP Center.Frontiers in surgery · 2022Article
- Impact of COVID-19 on liver disease: From the experimental to the clinic perspective.World journal of virology · 2021Review
- Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations.Human vaccines & immunotherapeutics · 2021Article
- Incidence, characteristics, and outcome of COVID-19 in patients on liver transplant program: a retrospective study in the north of Iran.New microbes and new infections · 2021Article
- COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence.Journal of clinical and translational hepatology · 2021Review
- Liver disease in the era of COVID-19: Is the worst yet to come?World journal of gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 pandemic has proven to be a serious challenge for the Spanish healthcare system. The impact of the virus on the liver is not well known, but in patients with chronic liver disease, mostly in advanced stages, it can critically compromise survival and trigger decompensation. Treatment in this subpopulation is complex due to the potential hepatotoxicity of some of the medicinal products used. Moreover, the pandemic has also negatively impacted patients with liver disease who have not contracted COVID-19, since the reallocation of human and material resources to the care of patients with the virus has resulted in a decrease in the treatment, diagnosis and follow-up of patients with liver disease, which will surely have negative consequences in the near future. Efficient reorganization of hepatology units is a priority to minimise the impact of the pandemic on a population as vulnerable as liver disease patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.